Impact of COVID-19 on GU Disease
The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. * Disclose if the patient has or had Genitourinary cancer or benign urologic condition * Provide urine specimen for research * Provide 4 tablespoons of blood for testing blood for research. * Provide permission to access medical records, such as patient lab results, medical history, imaging reports, etc.
Checked against the public recordLast updated Jan 31, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Subjects must be men and women 40 years of age or older * Subjects at risk or with GU cancer (Prostate, Bladder, Kidney) * Subjects with benign GU disorders ( BPH, UTI, Bladder infection and kidney stone) * Subjects must have a GU disease that requires clinic visit as determined by physician or healthcare provider following a telehealth appointment * Willing and able to provide blood and urine samples * Willing and able to complete a questionnaire to determine the COVID-19 symptoms. * Willing and able to sign informed consent form Exclusion Criteria: * Men and women below 40 years of age * Subjects do not have a GU disease
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Icahn School of Medicine at Mount SinaiNew York, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 31, 2025. Always confirm current availability with the study team.